Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: A matching-adjusted indirect comparison

Journal of Comparative Effectiveness Research

Volumn 5, Issue 2, 2016, Pages 129-139

  Swallow, Elyse ^a   Song, Jinlin ^a   Yuan, Yong ^b   Kalsekar, Anupama ^b   Kelley, Caroline ^a   Mu, Fan ^a   Kim, Soomi ^a   Noviello, Stephanie ^b   Signorovitch, James ^a  

^a ANALYSIS GROUP   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

daclatasvir; hepatitis C genotype 3; matching adjusted indirect comparison; peginterferon; ribavirin; sofosbuvir

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR PLUS SOFOSBUVIR; RIBAVIRIN PLUS SOFOSBUVIR; UNCLASSIFIED DRUG; ALPHA INTERFERON; BMS-790052; IMIDAZOLE DERIVATIVE; RIBAVIRIN; SOFOSBUVIR;

ADULT; ARTHRALGIA; ARTICLE; ASTHENIA; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; INSOMNIA; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT CARE; PRIORITY JOURNAL; PROPENSITY SCORE; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; GENOTYPE; HEALTH CARE QUALITY; MIDDLE AGED; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C; HUMANS; IMIDAZOLES; INTERFERON-ALPHA; MALE; MIDDLE AGED; RIBAVIRIN; SOFOSBUVIR; STANDARD OF CARE; TREATMENT OUTCOME;

EID: 84961805934     PISSN: 20426305     EISSN: 20426313     Source Type: Journal    
DOI: 10.2217/cer.15.49     Document Type: Article

References (37)

1. Lavanchy D. The global burden of hepatitis C. Liver Int. 29(Suppl. 1), 74-81 (2009).
2. Tapper EB, Afdhal NH. Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. J. Viral Hepat. 20(10), 669-677 (2013).
3. Leandro G, Mangia A, Hui J et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 130(6), 1636-1642 (2006).
4. Bochud PY, Cai T, Overbeck K et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J. Hepatol. 51(4), 655-666 (2009).
5. Nkontchou G, Ziol M, Aout M et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J. Viral Hepat. 18(10), e516-e522 (2011).
6. Jhaveri R, Mchutchison J, Patel K, Qiang G, Diehl AM. Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation. J. Infect. Dis. 197(2), 283-291 (2008).
7. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49(4), 1335-1374 (2009).
8. Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 368(20), 1878-1887 (2013).
9. Foster GR, Hézode C, Bronowicki JP et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 141(3), 881-889 e881 (2011).
10. Shiffman ML, Suter F, Bacon BR et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 357(2), 124-134 (2007).
11. Lagging M, Langeland N, Pedersen C et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 47(6), 1837-1845 (2008).
12. Larrey D, Ripault M-P, Pageaux G-P. Patient adherence issues in the treatment of hepatitis C. Patient Prefer. Adherence 8, 763 (2014).
13. American Association for the Study of Liver Diseases. Recommendations for testing, managing, and treating hepatitis C (2015). www.hcvguidelines.org/full-report-view
14. EASL. Recommendations of treatment of hepatitis C 2014. (2015). www.easl.eu/medias/cpg
15. European Medicines Agency. Epar summary for the public: sofosbuvir (sovaldi). www.ema.europa.eu/ema
16. Food and Drug Administration. Sovaldi (sofosbuvir). www.fda.gov
17. Zeuzem S, Dusheiko GM, Salupere R et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N. Engl. J. Med. 370(21), 1993-2001 (2014).
18. EASL recommendations on treatment of hepatitis C 2015. J. Hepatol. 63, 199-236 (2015).
19. European Medicines Agency. Epar summary for the public: Daklinza (daclatasvir). http://www.ema.europa.eu/docs
20. Food and Drug Administration. FDA approves new treatment for chronic hepatitis C genotype 3 infections. (2015). www.fda.gov
21. Nelson DR, Cooper JN, Lalezari JP et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: Ally-3 Phase 3 study. Hepatology 61(4), 1127-1135 (2015).
22. Ferenci P, Brunner H, Laferl H et al. A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa 2a in hepatitis C virus genotypes 2 and 3. Hepatology 47(6), 1816-1823 (2008).
23. Erder MH, Xie J, Signorovitch JE et al. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder. Appl. Health Econ. Health Policy 10(6), 381-395 (2012).
24. Signorovitch JE, Sikirica V, Erder MH et al. Matchingadjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health 15(6), 940-947 (2012).
25. Signorovitch JE, Wu EQ, Andrew PY et al. Comparative effectiveness without head-to-head trials. Pharmacoeconomics 28(10), 935-945 (2010).
26. Xie J, Juday T, Swallow E et al. Comparative efficacy at 48 weeks of atazanavir/ritonavir versus darunavir/ritonavir in treatment of naive hiv-1 patients: a matching adjusted indirect comparison of randomized trials. Presented at: ISPOR 17th Annual International Meeting. Washington, DC, 2-6 June 2012.
27. Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect. Dis. 15(1), 19 (2015).
28. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin. Gastroenterol. Hepatol. 9(6), 509-516 e501 (2011).
29. Jafferbhoy H, Gashau W, Dillon J. Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection. Clinicoecon. Outcomes Res. 2, 87 (2010).
30. Backx M, Lewszuk A, White J et al. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy. J. Viral Hepat. 21(3), 208-215 (2014).
31. Mitra D, Davis KL, Beam C, Medjedovic J, Rustgi V. Treatment patterns and adherence among patients with chronic hepatitis C virus in a us US managed care population. Value Health 13(4), 479-486 (2010).
32. Jacobson IM, Gordon SC, Kowdley KV et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N. Engl. J. Med. 368(20), 1867-1877 (2013).
33. Manns M, Zeuzem S, Sood A et al. Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. J. Hepatol. 55(3), 554-563 (2011).
34. Zeuzem S, Berg T, Moeller B et al. Expert opinion on the treatment of patients with chronic hepatitis C. J. Viral Hepat. 16(2), 75-90 (2009).
35. Signorovitch J, Ayyagari R, Cheng D, Wu EQ. Matchingadjusted indirect comparisons: a simulation study of statistical performance. Value Health 16(3), A48 (2013).
36. Foster GR, Pianko S, Cooper C et al. Sofosbuvir plus pegifn/rbv for 12 weeks vs sofosbuvir/rbv for 16 or 24 weeks in genotype 3 HCV infected patients and treatment experienced cirrhotic patients with genotype 2 HCV: the Boson study. Presented at: EASL-The International Liver Congress. Vienna, Austria 22-26 April 2015.
37. Chen J, Florian J, Carter W et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 144(7), 1450-1455 e1452 (2013).